2 BTKi in CLL
2.1 Covalent BTKi
2.1.1 Acalabrutinib
2.1.1.1 Phase 3 AMPLIFY trial
Acalabrutinib plus Venetoclax plus obinutuzumab (AVO) vs Acalabrutinib plus Venetoclax (AV)
2.1.2 Zanubritinib
2.1.2.1 ALPINE clinical trial
2.1.2.2 Phase 3 SEQUOIA study
2.1.2.2.1 Arm D Zanubritinib plus Ventoclax in treatment naive CLL/SLL
- Fixed duration (~2 years)
- 100%